Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio

Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product
Portfolio

NEWPORT, Ky., Oct. 29 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an
integrated specialty pharmaceutical company with both development and
commercial capabilities focused on women's healthcare and pain management,
announced today the completion of $50 million in equity financing. The round
was led by Longitude Capital with participation from new investors Skandia and
Silver Point Capital. Other current investors that participated in the
financing include MPM Capital, LLC, AIG Investments' sponsored funds,
Perseus-Soros Biopharmaceutical Fund, Blue Chip Venture Company, HealthCare
Ventures, LLC, and Union Springs, LLC. Aquilo Partners, L.P., a life science
investment bank, acted as the exclusive placement agent for the financing.

Michael J. Valentino, President and CEO commented, "I am extremely pleased to
have secured additional financial resources which will be used to support our
ongoing development and commercialization strategy for our emerging product
portfolio."

In June 2009, Xanodyne received Food and Drug Administration (FDA) approval
for Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules, a new treatment
option for relief of mild to moderate acute pain in adults (18 years of age or
older). Zipsor was launched nationally to physicians and patients in
September.

In addition, the company expects FDA action soon on Lysteda(TM) (formerly
XP12B), an oral tranexamic acid product under priority review. If approved,
Lysteda would be the first and only oral therapeutic agent indicated
specifically for the treatment of women suffering from cyclic heavy menstrual
bleeding.

Valentino added, "The continued commitment from our investor groups allows us
to remain focused on aggressively executing our product commercialization
plans and optimizing the other assets in our portfolio."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an
integrated specialty pharmaceutical company with both development and
commercial capabilities focused on women's healthcare and pain management.
Xanodyne markets a portfolio of products consisting of prescription
pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is
advancing a late stage pipeline of product candidates targeted at significant
potential markets in Xanodyne's focus areas.

SOURCE Xanodyne Pharmaceuticals, Inc.

Investors/Media: Rita O'Connor, +1-859-371-6383